VACV L1 Specific Neutra™ Antibody Products

Are you facing challenges in developing effective vaccines and therapies against poxvirus infections? Do you need reliable tools for your vaccinia virus research? Creative Biolabs' VACV L1 Specific Neutra™ Antibody Products help you achieve your research goals by providing high-quality, specific antibodies. Our antibodies are designed to target the vaccinia virus (VACV) L1 protein, a crucial factor in viral infection.

Introduction of VACV L1

The VACV L1 protein is integral to the life cycle of the vaccinia virus and is highly conserved among orthopoxviruses. As a component of the mature virion's membrane, L1 is expressed during the late stages of infection. This protein is crucial for viral entry and facilitates the fusion of host cells post-infection.

Structure

The characteristics of L1 membrane protein are its N-terminal ectodomain and C-terminal transmembrane domain. The ectodomain contains a compact architecture comprised of α-helices and β-sheets. A feature of L1 is its disulfide linkages, it is important for interaction with neutralizing antibodies. Scientific analyses detail L1 as comprising a cluster of α-helices aligned with two-stranded β-sheets. This research underscores the conserved amino terminus as a key region for L1's efficacy, emphasizing certain residues pivotal for N-myristoylation. Other amino acids influence viral entry without affecting myristoylation. L1's crystal structure, featuring loops connecting α-helices and β-sheets, is fundamental for its function.

Related Signaling Pathways

L1 protein is essential for VACV entry into host cells. This involves interactions with host receptors and viral proteins. L1 interacts with EFC components, crucial for viral core penetration into the cytoplasm. Recent research suggests L1 may act as a receptor-binding protein (RBP) by engaging host cell receptors.

Anti-VACV L1 Antibody Applications

Research Applications

Anti-VACV L1 antibodies are vital for basic poxvirus research. They're used in immunofluorescence microscopy, flow cytometry, and immunoprecipitation to study L1 protein expression, localization, and interactions with viral and host proteins. These studies reveal poxvirus infection and pathogenesis mechanisms.

Therapeutic Interventions

Anti-L1 antibodies effectively impede virus entry, underscoring their potential as therapeutic candidates. Anti-VACV L1 antibodies also hold promise for therapeutic interventions against poxvirus infections. These antibodies possess the capability to: 1. neutralize the virus; 2. inhibit its entry into host cells; 3. restrict the dissemination of infection.

Creative Biolabs is committed to offering researchers top-tier tools to advance virology research. Our VACV L1 Specific Neutra™ Antibody Products are designed to meet the needs of vaccine and therapeutic development.